VERA Stock Analysis: Buy, Sell, or Hold?
VERA - Vera Therapeutics, Inc. Class A Common Stock
$33.86
1.59 (4.91%)
▲
5d:
+7.05%
30d:
-4.49%
90d:
-0.53%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 19, 2026 at $32.03 · last confirmed Aug 21, 2026
Strength: 6.6/10
Get Alerted When VERA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
ℹ️ NEUTRAL: VERA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
ℹ️ NEUTRAL: VERA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VERA is currently trading at $33.86, which is considered fair relative to its 30-day fair value range of $30.55 to $35.83.
Technical Outlook: Technically, VERA is in a downtrend. Immediate support is located at $28.86, while resistance sits at $35.09. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $77.14 (+139.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VERA is in a downtrend. Immediate support is located at $28.86, while resistance sits at $35.09. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $77.14 (+139.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$30.55 -
$35.83
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading 139.0% below Wall St target ($77.14)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$30.55 -
$35.83
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$28.86
Resistance Level
$35.09
Current Trend
Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.31
Wall Street Target
$77.14
(+139.0%)
Share & Embed Analysis
Last updated: August 24, 2026 2:33 PM ET
Data refreshes hourly during market hours. Next update: 3:33 PM
Data refreshes hourly during market hours. Next update: 3:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VERA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Marshall Fordyce
SELL
22951 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 65 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 34 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 39 SELL |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 42 HOLD |
